TIAA Trust National Association Sells 319 Shares of GSK plc (NYSE:GSK)

TIAA Trust National Association cut its position in GSK plc (NYSE:GSK) by 4.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,736 shares of the pharmaceutical company’s stock after selling 319 shares during the quarter. TIAA Trust National Association’s holdings in GSK were worth $262,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Primecap Management Co. CA raised its position in shares of GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after buying an additional 10,407,905 shares in the last quarter. Mondrian Investment Partners LTD raised its holdings in shares of GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock valued at $205,920,000 after acquiring an additional 874,004 shares in the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in shares of GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after acquiring an additional 833,080 shares during the last quarter. Miller Howard Investments Inc. NY purchased a new position in shares of GSK during the fourth quarter worth about $23,366,000. Finally, Equity Investment Corp increased its position in shares of GSK by 13.3% in the fourth quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock worth $134,014,000 after purchasing an additional 466,327 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Price Performance

GSK stock opened at $38.74 on Friday. The firm has a market cap of $80.19 billion, a P/E ratio of 24.37, a P/E/G ratio of 1.12 and a beta of 0.58. The firm’s fifty day moving average is $37.22 and its 200 day moving average is $36.79. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.06%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is presently 98.74%.

Analyst Ratings Changes

Several equities research analysts have issued reports on GSK shares. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.